Guadagni F, Roselli M, Cosimelli M, Ferroni P, Spila A, Cavaliere F, Casaldi V, Wappner G, Abbolito M R, Greiner J W
Regina Elena Cancer Institute Rome, Italy.
Cancer Invest. 1995;13(2):227-38. doi: 10.3109/07357909509011692.
Among the new tumor markers that have been recently proposed, CA 72-4 is of particular interest, not only for its capabilities in diagnosing and monitoring certain neoplastic diseases, but also for its excellent specificity. Several studies focused on the potential clinical usefulness of CA 72-4 in gastrointestinal (GI) and gynecological cancer, showing a sensitivity of approximately 40% in colorectal and gastric cancer and 50% in ovarian cancer, with an overall specificity of more than 95%. Longitudinal evaluations of patients with either GI or gynecological malignant diseases demonstrated that significant elevations of CA 72-4 serum levels may be predictive of recurrent disease. Moreover, the combination of CA 72-4 with other known serum markers, such as CEA and CA 19-9 for GI cancer or CA 125 for ovarian cancer, indicated that an increase in the sensitivity can be achieved without substantial changes in the overall specificity, improving the possibility of monitoring these patients. In conclusion, these results provide a strong argument for the use of CA 72-4 in the management of these neoplastic diseases.
在最近提出的新型肿瘤标志物中，CA 72-4尤其受关注，这不仅是因为它在诊断和监测某些肿瘤疾病方面的能力，还因其出色的特异性。多项研究聚焦于CA 72-4在胃肠道（GI）和妇科癌症中的潜在临床应用价值，结果显示其在结直肠癌和胃癌中的敏感性约为40%，在卵巢癌中的敏感性为50%，总体特异性超过95%。对患有胃肠道或妇科恶性疾病的患者进行的纵向评估表明，CA 72-4血清水平的显著升高可能预示疾病复发。此外，将CA 72-4与其他已知血清标志物联合使用，如用于胃肠道癌症的癌胚抗原（CEA）和CA 19-9或用于卵巢癌的CA 125，结果表明在总体特异性无实质性变化的情况下可提高敏感性，从而增加了监测这些患者的可能性。总之，这些结果有力地支持了在这些肿瘤疾病的管理中使用CA 72-4。
